Recently, glial fibrillary acidic protein (GFAP) has garnered attention as a potentially valuable biomarker for various neurological disorders, including multiple sclerosis, frontotemporal dementia, AD, and Parkinson's disease. Here, GFAP is linked to Alzheimer disease.